K Braide1,2, J Kindblom3,4, U Lindencrona5,6, J Hugosson7, N Pettersson5,6. 1. Department of Urology, Institute of Clinical Sciences, University of Gothenburg, Gothenburg, Sweden. karin.braide@vgregion.se. 2. Department of Urology, Sahlgrenska University Hospital, Gothenburg, Sweden. karin.braide@vgregion.se. 3. Department of Oncology, Institute of Clinical Sciences, University of Gothenburg, Gothenburg, Sweden. 4. Department of Oncology, Sahlgrenska University Hospital, Gothenburg, Sweden. 5. Department of Radiation Physics, Institute of Clinical Sciences, The Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden. 6. Department of Medical Physics and Biomedical Engineering, Sahlgrenska University Hospital, Gothenburg, Sweden. 7. Department of Urology, Institute of Clinical Sciences, University of Gothenburg, Gothenburg, Sweden.
Abstract
PURPOSE: To quantify the relationship between the rectal dose distribution and the prevalence of self-reported rectal bleeding among men treated with salvage radiotherapy (ST) delivered by three-dimensional conformal radiotherapy (3DCRT) for prostate cancer. To use this relationship to estimate the risk of rectal bleeding for a contemporary cohort of patients treated with volumetric modulated arc therapy (VMAT) ST. METHODS AND PATIENTS: Rectal bleeding of any grade was reported by 56 (22%) of 255 men in a PROM-survey at a median follow-up of 6.7 years after 3DCRT ST. Treatment plan data were extracted and dose-response relationships for the rectal volumes receiving at least 35 Gy (V35Gy) or 63 Gy (V63Gy) were calculated with logistic regression. These relationships were used to estimate the risk of rectal bleeding for a cohort of 253 patients treated with VMAT ST. RESULTS: In the dose-response analysis of patients in the 3DCRT ST cohort, both rectal V35Gy and V63Gy were statistically significant parameters in univariable analysis (p = 0.005 and 0.003, respectively). For the dose-response models using either rectal V35Gy or V63Gy, the average calculated risk of rectal bleeding was 14% among men treated with VMAT ST compared to a reported prevalence of 22% for men treated with 3DCRT ST. CONCLUSIONS: We identified dose-response relationships between the rectal dose distribution and the risk of self-reported rectal bleeding of any grade in a long-term perspective for men treated with 3DCRT ST. Furthermore, VMAT ST may have the potential to decrease the prevalence of late rectal bleeding.
PURPOSE: To quantify the relationship between the rectal dose distribution and the prevalence of self-reported rectal bleeding among men treated with salvage radiotherapy (ST) delivered by three-dimensional conformal radiotherapy (3DCRT) for prostate cancer. To use this relationship to estimate the risk of rectal bleeding for a contemporary cohort of patients treated with volumetric modulated arc therapy (VMAT) ST. METHODS AND PATIENTS: Rectal bleeding of any grade was reported by 56 (22%) of 255 men in a PROM-survey at a median follow-up of 6.7 years after 3DCRT ST. Treatment plan data were extracted and dose-response relationships for the rectal volumes receiving at least 35 Gy (V35Gy) or 63 Gy (V63Gy) were calculated with logistic regression. These relationships were used to estimate the risk of rectal bleeding for a cohort of 253 patients treated with VMAT ST. RESULTS: In the dose-response analysis of patients in the 3DCRT ST cohort, both rectal V35Gy and V63Gy were statistically significant parameters in univariable analysis (p = 0.005 and 0.003, respectively). For the dose-response models using either rectal V35Gy or V63Gy, the average calculated risk of rectal bleeding was 14% among men treated with VMAT ST compared to a reported prevalence of 22% for men treated with 3DCRT ST. CONCLUSIONS: We identified dose-response relationships between the rectal dose distribution and the risk of self-reported rectal bleeding of any grade in a long-term perspective for men treated with 3DCRT ST. Furthermore, VMAT ST may have the potential to decrease the prevalence of late rectal bleeding.
Authors: Philip Poortmans; Alberto Bossi; Katia Vandeputte; Mathieu Bosset; Raymond Miralbell; Philippe Maingon; Dirk Boehmer; Tom Budiharto; Zvi Symon; Alfons C M van den Bergh; Christopher Scrase; Hendrik Van Poppel; Michel Bolla Journal: Radiother Oncol Date: 2007-08-13 Impact factor: 6.280
Authors: Jeff M Michalski; Hiram Gay; Andrew Jackson; Susan L Tucker; Joseph O Deasy Journal: Int J Radiat Oncol Biol Phys Date: 2010-03-01 Impact factor: 7.038
Authors: Stephen A Boorjian; R Houston Thompson; Matthew K Tollefson; Laureano J Rangel; Eric J Bergstralh; Michael L Blute; R Jeffrey Karnes Journal: Eur Urol Date: 2011-02-22 Impact factor: 20.096
Authors: Adil S Akthar; Anthony C Wong; Akash D Parekh; Greg Hubert; Christina H Son; Charles A Pelizzari; Stanley L Liauw Journal: Adv Radiat Oncol Date: 2018-05-08